The topic of todays work is "what to do in the face of

New Post Public Reply Private Reply Replies (1) Message Board
biomanbaba TOB #99

The topic of todays work is "what to do in the face of the CTIX news GAP".
I have tried for the longest to put together a TIMELINE with regards to the
release of quantitative information from the company. I have failed and not due
to any lack of effort. Leo Ehrlich has backed off from his declaration that
that shareholders would be DELUGED with data to a stance where he reminds us
that actual release has to pass through the hands of the Principal Investigator.
The conduct of our Principal Investigator has to be studied in the context
of a broader framework. The perspective gained from Anthropology is highly useful
in understanding what behavior to expect from the Principal Investigator.
First one needs to understand that the elite group of persons within American
culture that are a subculture we call the Journal Editors have enormous control
over the conduct of Principal Investigators. To see a parallel in tribal culture
to the relationship one would have to look to the relationship between SHAMANS and
and juvenile members of a tribe. Principal Investigators have a need to pass muster
with and gain the approval of Journal Editors like they were children in some tribe
going through a right of passage. One of the rules associated the right of passage
is that new science presented for publication must be VIRGIN. Every editor wants his
publication to be the FIRST to announce to the world what has been discovered.
Allowing us to see much of the quantitative information we would like would be
equal to the tribal juveniles allowing someone to have sex with a VIRGIN they were
task by the SHAMAN with guarding.
Let me pause to discuss the term "NEWS GAP". When in the future you get a quickly
written piece from me while I am SPLIT SCREEN and trading or just too busy; understand
that this means the ABSENCE of Trial data. In my conversations recently with buy and
hold investors they want to pound the table with me about "other" upcoming news
such as the PRURISOL trail start or new funding etc. Those thing are nice but they are
collateral to the CATALYST NEWS CYCLE and not a part OF IT.
As asset allocators we want to be OVERWEIGHT the next CATALYST. I believed in December
when I heard the DELUGE remark that we would see actual quantitative confirmation
of P53 activation sooner than this writing. I was wrong. The result of that fact is
that my call to OVERWEIGHT CTIX has caused my followers to become BAG HOLDERS in the short
run. I have no doubt about the LONG TERM PROSPECTS for CTIX; I believe they are excellent.
I no longer believe a SHORT RUN OVERWEIGHT is called for. I am out at 1.85
My current model is 60% CLSN 5% SBFM and 35% cash. My basis take off on CLSN
which we expect to happen in a FEW DAYS will be added to my cash position. I expect
the bashers and shorts to DOMINATE discussion on IHUB during the relevant SHORT RUN PERIOD
in SPITE of the best efforts of some on this list to produce a different result.
This view is subject to CHANGE. A crammer caveat I follow is "when the facts change
you must change your investment thesis". Mr Ehrlich could change my view in a heartbeat
but he is in my view WEARING A SET OF HANDCUFFS placed on him by the allegiance of
the PRINCIPAL INVESTIGATOR to the dictates of the SHAMANS.
My take off on CLSN will be accomplished entirely by selling to close my APR 2013
calls. My Jan 2014s will be held for EXERCISE in the future hopefully when the share price
approached $40. I will hold my strong cash position until the FACTS favor a reallocation
and will write when I see it happen.

BIOMANBABA

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 157

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 70

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 192

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Analysis of Strategy Inc's Recent Stock Performance

Updated Category News Views 143

Strategy Inc (NASDAQ: MSTR) Faces Critical Trading Challenges Strategy Inc stock recently closed at $300.70, marking a notable decline of approximately 7%. This downturn has positioned the stock at a pivotal moment in its trading journey, stirring discussions among analysts and investors alike. Technical Analysis Reveals Breakdown Risks Following a series of downward...

Continue Reading
Major Bank Stock Opportunities Following Fed's Rate Reductions

Updated Category News Views 77

Major Bank Stock Opportunities Following Fed's Rate Reductions The recent cut in interest rates by the Federal Reserve marks a crucial shift in the banking industry, especially for mid- and small-cap banks. With a reduction of 50 basis points, this decision indicates a new phase that could improve profitability across the banking sector. Analyst Steven Alexopoulos at...

Continue Reading
SafeRent Resolves Discrimination Lawsuit with $2.3M Settlement

Updated Category News Views 519

SafeRent Settles Discrimination Lawsuit for $2.3 Million SafeRent Solutions, a leading AI-driven tenant screening service, has successfully settled a class action lawsuit aimed at its screening practices. The case, filed in a Massachusetts court, raised significant concerns regarding the treatment of low-income renters. Details of the Settlement Recently, U.S. District...

Continue Reading
Medical Experts Rally Behind RFK Jr. for HHS Leadership

Updated Category News Views 496

Support from Medical Professionals for RFK Jr. Leadership In a compelling demonstration of support, more than 800 medical professionals have signed a letter endorsing Robert F. Kennedy Jr. for the position of Secretary of Health and Human Services (HHS). This unified action showcases the broad consensus among healthcare leaders that significant reforms are essential to...

Continue Reading
Lundin Gold's Exploration Uncovers Exceptional Porphyry Grades

Updated Category News Views 169

Exciting Developments in Exploration for Lundin Gold Lundin Gold Inc. (TSX: LUG) has made remarkable progress in its exploration activities at the Fruta del Norte (FDN) gold mine, revealing outstanding porphyry mineralization that showcases significant copper and gold potential. The mining company is currently focusing its efforts on three areas of interest: Sandia,...

Continue Reading